STADA Arzneimittel AG has licensed 3M Drug Delivery Systems’ transdermal patch technology for the transdermal delivery of the opioid pain medication fentanyl. Terms of the agreement were not disclosed.
The 3M Patent (EP 2158905) was granted on March 20, 2013 and enables the transdermal drug delivery of a therapeutically effective amount of fentanyl across the skin of a patient. The matrix device incorporates fentanyl into an adhesive matrix made of a copolymer containing alkyl acrylate and other monomers.
STADA Licenses Transdermal Patch from 3M DDS
Published November 20, 2013
blog comments powered by Disqus